Semisynthetic p‐Coumaric Acid Derivatives as Lead Dual Inhibitors Against DPP‐IV and GSK‐3β for Antidiabetic Therapy
Chemical Biology & Drug Design · 2024
DOI: 10.1111/cbdd.70016 ↗At a glance
Journal article in Chemical Biology & Drug Design, 2024. Written by Heberth de Paula and 8 co-authors. Institution: Centro de Ciências Exatas, Naturais e da Saúde, Universidade Federal Do Espírito Santo, Alegre, ES, Brazil. Major MEDLINE topics: Coumaric Acids, Glycogen Synthase Kinase 3 beta, Molecular Dynamics Simulation, Molecular Docking Simulation. Cited 4 times so far (Crossref); 48 references.
Abstract (original language)
Type 2 diabetes mellitus is a dramatically increasing global public health challenge. The prevalence is projected almost double, from 194 million in 2003 to 333 million in 2025 with type 2 diabetes mellitus representing approximately 90%–95% of cases. Dual inhibitors for antidiabetic targets is still novel and promising strategy for discovery of more effective therapies. Ester and triazole derivatives of p ‐coumaric acid were obtained from Williamson synthesis and Microwave‐assisted click reaction, respectively. Chemical structures were finely characterized through IR, 1H, and 13C NMR and HRMS. They were tested for their dual inhibitory activity against GSK‐3β kinase and DPP‐IV. The complexes resulting from docking were used for all‐atom molecular dynamics simulations, including the enzymes in the apo form, using the GROMACS 2022.3. Two inhibitors 2 and 5 demonstrated promising inhibition at low and submicromolar against both proteins. Molecular Dynamic simulations revealed that the binding pattern of the control inhibitors were reproduced by p‐coumaric acid derivatives 2 and 5 with crucial interactions involving the same residues. The p‐coumaric skeleton can be considered as a promising core for GSK‐3β kinase and DPP‐IV dual inhibitors.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centro de Ciências Exatas, Naturais e da Saúde, Universidade Federal Do Espírito Santo, Alegre, ES, Brazil.
- Programa de Pós-Graduação Em Agroquímica, Universidade Federal Do Espírito Santo, Alegre, ES, Brazil.
- Programa de Pós-Graduação Em Química, Universidade Federal Do Espírito Santo, Vitória, ES, Brazil.
- Centro de Ciências Naturais e Humanas, Universidade Federal Do ABC, Santo Andre, SP, Brazil.
- Escola de Artes, Ciências e Humanidades, University of São Paulo, São Paulo, SP, Brazil.
ORCID profiles: Pedro Alves Bezerra Morais
Cite
APA
de Paula, H., Bolsoni, C. S., de Souza, F. F., Fonseca, V. D. R., Romão, W., de Sairre, M. I., Honorio, K. M., Lacerda, V., & Morais, P. A. B. (2024). Semisynthetic p‐Coumaric Acid Derivatives as Lead Dual Inhibitors Against DPP‐IV and GSK‐3β for Antidiabetic Therapy. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70016
Vancouver
de Paula H, Bolsoni CS, de Souza FF, Fonseca VDR, Romão W, de Sairre MI, et al. Semisynthetic p‐Coumaric Acid Derivatives as Lead Dual Inhibitors Against DPP‐IV and GSK‐3β for Antidiabetic Therapy. Chemical Biology & Drug Design. 2024. doi:10.1111/cbdd.70016
BibTeX
@article{dePaula2024,
author = {de Paula, Heberth and Bolsoni, Camilla Santos and de Souza, Fernanda Fernandes and Fonseca, Victor Da Rocha and Romão, Wanderson and de Sairre, Mirela Ines and Honorio, Kathia Maria and Lacerda, Valdemar and Morais, Pedro Alves Bezerra},
title = {Semisynthetic p‐Coumaric Acid Derivatives as Lead Dual Inhibitors Against DPP‐IV and GSK‐3β for Antidiabetic Therapy},
journal = {Chemical Biology & Drug Design},
year = {2024},
doi = {10.1111/cbdd.70016}
}
EUVIMED